⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 2, 2024Clinical and Molecular HepatologyOpen Access

Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation

Soon Kyu Lee Ho Joong Choi Young Kyoung You Pil Soo Sung Seung Kew Yoon Jeong Won Jang Jong Young Choi

View Full Paper

Ask AI

Bookmark

Share

Abstract

This study aimed to identify the risk factors for chronic kidney disease (CKD) and end-stage renal disease (ESRD) following liver transplantation (LT), with a specific focus on tacrolimus levels and intrapatient variability (IPV).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lee et al. (2024) studied this question.

synapsesocial.com/papers/68e55ef6e2b3180350efc558 https://doi.org/10.3350/cmh.2024.0451

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Impact of tacrolimus trough level variability on graft outcomes in low-immunological risk kidney transplantationCohort Study · 2026
2The predictive value of tacrolimus intrapatient variability and time in therapeutic range for renal transplant outcomes2025
3Influence of Tacrolimus Intrapatient Variability on Allograft Rejection Frequency and Survival Following Liver Transplantation2024 · 5 citations
4Optimum tacrolimus trough levels for enhanced graft survival and safety in kidney transplantation: a retrospective multicenter real-world evidence study2024 · 11 citations
5Tacrolimus Variability and Clinical Outcomes in the Early Post-lung Transplantation Period: Oral Versus Continuous Intravenous Administration2024 · 7 citations